12 results
To assess long-term safety and tolerability of pitavastatin 4 mg once daily (QD)To assess the efficacy of pitavastatin (4 mg QD) and simvastatin (40 mg and 80 mg QD) in terms of LDL-C target attainment (European Atherosclerosis Society [EAS] and…
1. Is PmsALG comparable with PmsINSP, even with changing Ppl?2. Is PmsARM comparable with PmsINSP and PmsALG?3. Does thoracic drainage have influence on pleural pressures measured by esophageal balloon catheter to determine transpulmonary pressure?4…
The primary objective of this study is to evaluate the efficacy of different doses of TA 8995, a cholesteryl ester transfer protein (CETP) inhibitor, on the elevation of high density lipoprotein cholesterol (HDL C) and reduction of low density…
To evaluate anti-inflammatory effects of statin therapy on vessel wall inflammation by means of FDG PET/CT in AS patients.
Primary objective:To assess the effect of multiple dose atorvastatin on the steady state pharmacokinetics of raltegravir and vice versa by intrasubject comparison in healthy subjects.• The comparison of steady state raltegravir (400 mg BID for 7…
To study the protective effect of pretreatment (both 3 day and 7 day) with rosuvastatin and atorvastatin on flow mediated dilation after 15 minutes ischemia and 15 minutes reperfusion.
To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm. This to confirm results from our previous study.
Determine if maximum doses of atorvastatin are safe in patients infected with chronic hepatitis C and if the so called pleiotropic effects of atorvastatin cause a decrease in the HCV viral load.
To investigate whether statin treatment can prevent or delay the development of RA in persons at increased risk of RA.
to evaluate the anti-inflammatory effects of 3 months statin therapy on vessel wall inflammation by means of FDG PET/CT in patients with CKD
Primary objective:To assess the effect of 12 weeks of GSK3228836 on serum hepatitis B virus surface antigen (HBsAg) levels in participants with CHBSecondaryEfficacy: To assess sustainability of serum HBsAg loss by GSK3228836 for up to 24 weeks off-…
Primary objectives: To assess the extent of vascular wall inflammation in DM type 2 patients and the residual risk after 3 months of high dosage statin therapy, as measured with 68Ga-Dotatate PET-CT. Secondary objectives: To assess the feasibility…